Literature DB >> 19720253

Combined endoscopic and minitrephination techniques in the surgical management of frontal sinus type IV cell disease.

Patricia A Maeso1, Robert T Deal, Stilianos E Kountakis.   

Abstract

OBJECTIVE: The aim of the study was to present minimally invasive combined endoscopic and minitrephination techniques in the surgical management of frontal sinus type IV cell disease.
METHODS: Case report of a 44-year-old man with localized pain in the right forehead. Computed tomography of the sinus revealed an opacified expanding type IV cell within the right frontal sinus, draining into the frontal sinus itself. An endoscopic approach through the frontal recess was not successful in reaching this cell. A minitrephination approach was then used and an endoscope was inserted through the trephination hole. Instruments were inserted endoscopically into the right frontal sinus through the frontal recess and then using direct endoscopic visualization through the minitrephination access, the frontal cell was opened and marsupialized.
RESULTS: The patient recovered uneventfully with his localized frontal pain completely resolved 3 years after surgery.
CONCLUSION: The minitrephination approach can be used to introduce an endoscope into the frontal sinus to assist in the surgical management of remote cephalad and lateral lesions within the sinus that are otherwise difficult to reach using endoscopic techniques alone.

Entities:  

Mesh:

Year:  2008        PMID: 19720253     DOI: 10.1016/j.amjoto.2008.06.012

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  2 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  Mini-endoscopy of the frontal sinus to guide endonasal frontal sinus surgery.

Authors:  Basel Al Kadah; Bernhard Schick
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-30       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.